Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Plastic Surgery Market: Fat Grafting Grabs A Hefty Slice Of The Plastics Pie

Executive Summary

Fat, fillers, and a "funnel" that may minimize a common cause of breast implant complications are among the hot topics in both aesthetic and reconstructive plastic surgery. Meanwhile, the acquisition by Actavis of Allergan – a leading player in the aesthetics market with BOTOX and breast implants – has the combined company poised for long-term double-digit revenue and earnings growth.

You may also be interested in...



Facial Aesthetics Market: New Technologies Address Consumer Demand

Consumers of aesthetic procedures are still looking for the perfect option – one that produces a more youthful looking face, but does not require much, if any, downtime. Ideally, these consumers also would like something that offered a long-lasting effect and was delivered with minimal pain and discomfort. At the 2011 AAFPRS conference, held recently in San Francisco, CA, the Emerging Trends and Technologies session focused on new and developing technologies that could meet some of these demands.

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

MT035722

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel